Fueled by increasing investments from biotech, Charles River expects to double the size of its business over the next five years – organically and through M&A – to become a ‘more responsive partner,’ says CEO.
Alnylam’s first-in-class drug approved, manufacturing no ‘trivial undertaking’
from in-PharmaTechnologist.com
US FDA grants Breakthrough Therapy Designation for food allergy drug Xolair
from BioPharma-Reporter.com
US FDA approves first non-gene edited allogeneic CAR T-cell candidate for trials
from BioPharma-Reporter.com
CSL’s profits up 30%, explaining 1.8m-sq-ft Illinois operation expansion
from in-PharmaTechnologist.com
Robotics, automation to play a ‘fundamental role’ in Icon’s continued success: Q2 earnings call
Clinical evolution
Jerusalem’s Hadassah Medical Center joins TriNetX network
Globalization
PSI CRO continues growth in Asia-Pacific
Globalization
EMA pulls back on activity, with 30%+ staff losses expected
Globalization
